DJIA 17,801.75 -13.19 -0.07%
NASDAQ 4,769.32 11.07 0.23%
S&P 500 2,069.31 2.28 0.11%
market minute promo

TESARO (NASDAQ: TSRO)

33.80 -0.11 (-0.32%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

TSRO $33.80 -0.32%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $33.63
Previous Close $33.91
Daily Range $33.59 - $34.03
52-Week Range $22.15 - $40.99
Market Cap $1.2B
P/E Ratio -8.13
Dividend (Yield) $0.00 (0.0%)
Volume 19,685
Average Daily Volume 389,462
Current FY EPS -$4.57

Sector

Healthcare

Industry

Drugs

TESARO (TSRO) Description

TESARO Inc. is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. Website: http://www.tesarobio.com/

News & Commentary Rss Feed

What Was Behind Tesaro Inc.'s 21% Pop?

Tesaro and Opko's rolapitant successfully achieved primary and secondary endpoints in reducing chemotherapy-induced nausea and vomiting.

Myriad Genetics, Tesaro Tie Up for myChoice Cancer Test - Analyst Blog

TESARO's (TSRO) CEO Lonnie Moulder on Q3 2014 Results - Earnings Call Transcript

Benzinga's Top Initiations

Weakness Seen in Tesaro, Inc. (TSRO): Stock Tumbles 9.0% - Tale of the Tape

TESARO Announces Offering of $165 Million of Convertible Senior Notes Due 2021

TRACON Pharmaceuticals Completes $27M Financing And Expands Management Team And Board of Directors

TESARO Seeks FDA Approval for NK-1 Receptor Rolapitant - Analyst Blog

TESARO Seeks FDA Approval for NK-1 Receptor Rolapitant - Analyst Blog

Sector Update: Health Care Stocks End Mixed; Opko Health, Tesaro Climb After Submitting New Drug Ap

Sector Update: Health Care Stocks End Mixed; Opko Health, Tesaro Climb After Submitting New Drug Application for Anti-Nausea Medication

Sector Update: Health Care

TESARO Announces Submission Of Rolapitant New Drug Application To FDA

TESARO Announces Submission Of Rolapitant New Drug Application To FDA

See More TSRO News...